Literature DB >> 25996795

Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis.

Christopher J Ryerson1, Darragh O'Connor2, James V Dunne2, Fran Schooley3, Cameron J Hague4, Darra Murphy4, Jonathon Leipsic4, Pearce G Wilcox5.   

Abstract

BACKGROUND: Mortality risk prediction tools have been developed in idiopathic pulmonary fibrosis, however, it is unknown whether these models accurately estimate mortality in systemic sclerosis-associated interstitial lung disease (SSc-ILD).
METHODS: Four baseline risk prediction models--the Composite Physiologic Index, the Interstitial Lung Disease-Gender, Age, Physiology Index, the du Bois index, and the modified du Bois index--were calculated for patients recruited from a specialized SSc-ILD clinic. Each baseline model was assessed using logistic regression analysis with 1-year mortality as the outcome variable. Discrimination was quantified using the area under the receiver operating characteristic curve. Calibration was assessed using the goodness-of-fit test. The incremental prognostic ability of additional predictor variables was determined by adding prespecified variables to each baseline model.
RESULTS: The 156 patients with SSc-ILD completed 1,294 pulmonary function tests, 725 6-min walk tests, and 637 echocardiograms. Median survival was 15.0 years from the time of SSc-ILD diagnosis. All baseline models were significant predictors of 1-year mortality in SSc-ILD. The modified du Bois index had an area under the receiver operating characteristic curve of 0.84, compared with 0.77 to 0.81 in the other models. Calibration was acceptable for the modified du Bois index, but was poor for the other models. All baseline models include FVC and 6-min walk distance was identified as an additional independent predictor of 1-year mortality.
CONCLUSIONS: The modified du Bois index has good discrimination and calibration for the prediction of 1-year mortality in SSc-ILD. FVC and 6-min walk distance are important independent predictors of 1-year mortality in SSc-ILD.

Entities:  

Mesh:

Year:  2015        PMID: 25996795     DOI: 10.1378/chest.15-0003

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Authors:  Julie Morisset; Eric Vittinghoff; Bo Young Lee; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jay H Ryu; Kirk D Jones; Stefania Cerri; Andreina Manfredi; Marco Sebastiani; Andrew J Gross; Brett Ley; Paul J Wolters; Talmadge E King; Dong Soon Kim; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-22       Impact factor: 3.415

2.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

3.  Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease.

Authors:  Robert L Mango; Eric L Matteson; Cynthia S Crowson; Jay H Ryu; Ashima Makol
Journal:  Lung       Date:  2018-05-21       Impact factor: 2.584

Review 4.  Lung Manifestations in the Rheumatic Diseases.

Authors:  Tracy J Doyle; Paul F Dellaripa
Journal:  Chest       Date:  2017-05-25       Impact factor: 9.410

5.  Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.

Authors:  David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

6.  Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.

Authors:  Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

7.  Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Authors:  Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho
Journal:  BMC Pulm Med       Date:  2017-01-13       Impact factor: 3.317

8.  Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Authors:  Dinesh Khanna; Donald P Tashkin; Christopher P Denton; Elisabetta A Renzoni; Sujal R Desai; John Varga
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

9.  Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease.

Authors:  Elizabeth R Volkmann; Aryeh Fischer
Journal:  J Scleroderma Relat Disord       Date:  2020-05-22

10.  Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study.

Authors:  Chrystal Chan; Christopher J Ryerson; James V Dunne; Pearce G Wilcox
Journal:  BMC Pulm Med       Date:  2019-10-31       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.